IDEXX Laboratories/$IDXX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About IDEXX Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Ticker

$IDXX
Primary listing

Industry

Health Care Equipment & Supplies

Employees

11,000

ISIN

US45168D1046

IDXX Metrics

BasicAdvanced
$42B
48.07
$10.82
1.52
-

What the Analysts think about IDXX

Analyst ratings (Buy, Hold, Sell) for IDEXX Laboratories stock.

Bulls say / Bears say

IDEXX Laboratories reported strong fourth-quarter earnings for 2024, with revenue reaching $954 million, surpassing the expected $935 million, driven by robust demand for its animal testing products and higher prices. (Monexa)
The company's Companion Animal Group (CAG) segment continues to be a key growth driver, benefiting from the increasing trend of pet humanization, with pet owners willing to spend more on advanced diagnostics and healthcare for their animals. (Monexa)
IDEXX Laboratories has demonstrated strong financial health, with net income growing at a CAGR of 15.5% since 2013, and free cash flow increasing at a CAGR of 13.4% in the same period, showcasing the company's operational efficiency and ability to generate cash from its operations. (Nasdaq)
IDEXX Laboratories has lowered its annual revenue forecast for the third time due to a decrease in veterinary clinic visits amid inflationary pressures and staffing challenges, now anticipating full-year revenue between $3.87 billion and $3.89 billion, down $38 million from previous predictions. (Reuters)
The company has a net debt of around $1 billion, which may raise concerns among investors about its financial leverage and potential risks associated with debt servicing. (Nasdaq)
IDEXX Laboratories' operating margin has seen a slight decline, with the fourth quarter of 2023 reporting a margin of 27.2%, down from 27.3% in the same period the previous year, indicating potential challenges in maintaining profitability. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

IDXX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IDXX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IDXX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs